Director/PDMR Shareholding

By

Regulatory News | 01 Oct, 2018

Updated : 15:30

RNS Number : 5835C
Clinigen Group plc
01 October 2018
 

1 October 2018

 

 

PDMR SHAREHOLDINGS

 

Further to the Result of Placing announcement on Thursday 27 September 2018 regarding the placing of 9,467,456 new ordinary shares (the "Placing Shares"), Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company') announces the following PDMR dealings in accordance with Article 19 of the Market Abuse Regulation:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Shaun Chilton

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

213800OBIKGI2JYYS227

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Director participation in Placing

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

845p per share

7,101

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

7,101

845p

£60,003.45

f)

Date of the transaction

1 October 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Anne Hyland

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

213800OBIKGI2JYYS227

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Director participation in Placing

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

845p per share

4,142

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

4,142

845p

£34,999.90

f)

Date of the transaction

1 October 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

-Ends-

 

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Martin Abell, Group Chief Financial Officer

Matt Parrish, Head of Investor Relations




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)

 

 


RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw

Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

 

For more information, please visit www.clinigengroup.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLLFFSIDLLIIT

Last news